Exercise Intolerance: Labs, Causes, and Next Steps

What Exercise Intolerance Actually Means

Exercise intolerance is not simply being "out of shape." It refers to a reproducible, disproportionate reduction in the ability to perform physical work relative to age- and sex-matched norms, typically accompanied by fatigue, dyspnea, muscle weakness, or chest discomfort that limits activity. The 2022 AHA/ACC Guideline for the Diagnosis and Management of Heart Failure states that "exercise intolerance is the cardinal symptom of heart failure with preserved ejection fraction (HFpEF)" and provides a central diagnostic criterion for the condition. (1)

Objective vs. Subjective Exercise Intolerance

Patients often describe the symptom differently: some notice they cannot climb one flight of stairs without stopping; others report that a brisk 10-minute walk now triggers 20 minutes of recovery. Objective measurement matters because self-reported activity tolerance correlates poorly with measured VO2 peak. A 2018 study in the Journal of the American College of Cardiology (N=455) found that only 41% of patients with objectively reduced VO2 peak (<80% predicted) reported significant dyspnea on standard questionnaires, meaning subjective tolerance substantially under-captures physiological limitation. (2)

Why Symptom Duration and Trajectory Matter

Sudden-onset exercise intolerance (days to 2 weeks) suggests acute pathology: new-onset atrial fibrillation, myocarditis, pulmonary embolism, or acute anemia from bleeding. Gradual onset over months points toward chronic conditions including hypothyroidism, advancing heart failure, or metabolic syndrome. Documenting the trajectory guides triage and test selection before a single tube of blood is drawn.

Common Causes of Exercise Intolerance

Exercise intolerance is a symptom, not a diagnosis. The physiological bottleneck can be cardiovascular, pulmonary, hematologic, metabolic, neuromuscular, or deconditioning-related, and more than one driver is often present at the same time.

Cardiovascular Causes

Heart failure with preserved ejection fraction (HFpEF) is the single most frequently missed cardiovascular cause. An estimated 3 to 6% of the general population and up to 50% of all heart failure patients have HFpEF, the majority of whom present primarily with exercise intolerance rather than resting dyspnea or edema. (3) Coronary artery disease, hypertrophic cardiomyopathy, and significant valvular disease (particularly aortic stenosis and mitral regurgitation) are additional structural causes. Arrhythmias, especially paroxysmal atrial fibrillation, may produce episodic rather than continuous intolerance.

Pulmonary Causes

Chronic obstructive pulmonary disease (COPD) and asthma reduce ventilatory reserve and directly cap exercise capacity. The GOLD 2023 guidelines report that over 50% of patients with GOLD Stage II COPD experience exercise intolerance before they report significant resting dyspnea, making exercise capacity an early clinical signal. Interstitial lung disease and pulmonary hypertension are less common but produce severe limitation. Exercise-induced bronchoconstriction (EIB) affects an estimated 10% of the general population and up to 90% of competitive athletes with asthma. (4)

Hematologic and Iron-Related Causes

Iron-deficiency anemia reduces oxygen-carrying capacity and is one of the most correctable causes of exercise intolerance. Even iron deficiency without overt anemia (low ferritin with normal hemoglobin) impairs mitochondrial function and limits VO2 max. A randomized controlled trial published in The Lancet (N=373) found that intravenous ferric carboxymaltose in iron-deficient patients with heart failure improved the 6-minute walk distance by 33 meters over 24 weeks (P<0.001) compared to placebo. (5)

Hormonal and Metabolic Causes

Hypothyroidism reduces cardiac output, impairs skeletal muscle oxidative capacity, and lowers VO2 peak. The American Thyroid Association notes that symptomatic hypothyroidism produces measurable reductions in peak exercise capacity even at TSH levels only modestly elevated above the reference range. (6)

Testosterone deficiency in men is independently associated with reduced exercise capacity. A 12-week RCT published in JAMA (N=209) found that testosterone therapy in hypogonadal men (total testosterone <300 ng/dL) increased 6-minute walk distance by a mean of 57 meters vs. Placebo (P<0.001). (7) Insulin resistance and type 2 diabetes impair skeletal muscle glucose uptake during exercise, reduce mitochondrial biogenesis, and blunt cardiac output response to exertion. Patients with poorly controlled type 2 diabetes (HbA1c above 9%) show VO2 peak reductions averaging 20 to 30% relative to age-matched controls. (8)

Deconditioning

Deconditioning from prolonged inactivity, bed rest, or sedentary lifestyle produces measurable decrements in VO2 max at a rate of approximately 1% per day of complete bed rest. At 4 weeks of strict bed rest, VO2 max drops by 26% on average. This is reversible but can be misattributed to occult disease if a thorough history is not taken. (9)

Post-COVID and Long-COVID Exercise Intolerance

Post-acute sequelae of SARS-CoV-2 (PASC) now represent a recognized cause of exercise intolerance, distinct from deconditioning. A 2022 study in Nature Medicine (N=3,762) documented that 22% of COVID survivors reported significant exercise intolerance at 12 months post-infection, with CPET findings consistent with peripheral muscle oxygen extraction deficits rather than cardiac limitation. (10)

The Right Lab Panel for Exercise Intolerance

Labs should be ordered as a targeted panel, not as a random "check everything" screen. The goal is to identify reversible drivers that explain the symptom, or to stratify cardiac risk before advanced testing.

First-Line Blood Tests

The following panel is appropriate for essentially all adults presenting with unexplained exercise intolerance:

• CBC with differential: identifies anemia, polycythemia, and infection-related causes.
• Comprehensive metabolic panel (CMP): screens for renal dysfunction, liver disease, and electrolyte abnormalities (hypokalemia and hypomagnesemia both impair muscle function).
• TSH: hypothyroidism and hyperthyroidism each produce distinct patterns of exercise intolerance.
• Fasting glucose and HbA1c: undiagnosed or poorly controlled diabetes is a common contributor.
• Iron studies: serum iron, TIBC, transferrin saturation, and ferritin. A ferritin below 30 mcg/L is consistent with iron deficiency even without anemia.
• BNP or NT-proBNP: BNP above 35 pg/mL or NT-proBNP above 125 pg/mL should prompt echocardiography and cardiology referral per the 2022 AHA/ACC Heart Failure Guidelines. (1)
• Lipid panel: hyperlipidemia is a cardiovascular risk factor that shapes downstream testing decisions.

Second-Line and Hormone-Specific Labs

When the first-line panel is unrevealing or when hormonal deficiency is clinically suspected, add:

• Total and free testosterone (morning sample, 8 to 10 AM for men): hypogonadism is defined as total testosterone <300 ng/dL plus symptoms by the American Urological Association. (11)
• Free T3 and free T4: if TSH is abnormal or borderline.
• Cortisol (AM): adrenal insufficiency produces profound exercise intolerance and is frequently missed.
• Vitamin D (25-OH): severe deficiency (<20 ng/mL) impairs skeletal muscle oxidative phosphorylation.
• Aldosterone and renin: if hypertension and fatigue coexist, primary hyperaldosteronism is worth excluding.

Cardiac Biomarkers and Imaging

An ECG is the minimum cardiac evaluation for any new-onset exercise intolerance. An abnormal ECG (ST changes, LVH pattern, right heart strain) should prompt echocardiography. In patients over 50 with cardiovascular risk factors, stress echocardiography or nuclear stress testing assesses for inducible ischemia. NT-proBNP has a high negative predictive value for ruling out significant cardiac dysfunction when below 125 pg/mL. (1)

Cardiopulmonary Exercise Testing: The Gold Standard

CPET is the most diagnostically informative single test for exercise intolerance. It measures VO2 peak, ventilatory efficiency (VE/VCO2 slope), anaerobic threshold, heart rate reserve, and oxygen pulse simultaneously during a maximal or symptom-limited exercise protocol.

What CPET Measures and Why It Matters

A VO2 peak below 80% of predicted age- and sex-matched values defines objectively reduced exercise capacity. The pattern of limitation guides diagnosis: a flat oxygen pulse curve suggests cardiac output limitation; an elevated VE/VCO2 slope above 36 suggests either pulmonary hypertension or heart failure; an early anaerobic threshold with preserved heart rate reserve suggests peripheral muscle limitation from deconditioning or metabolic disease. The AHA's 2021 Scientific Statement on CPET states that "VO2 peak is the single strongest prognostic marker in patients with dyspnea of unexplained etiology." (12)

When to Order CPET

CPET is appropriate when:

1. First-line labs and echocardiography do not explain the symptom.
2. Dyspnea persists after treating an identified cause, and further titration depends on quantifying residual limitation.
3. Pre-transplant or pre-surgical risk stratification is needed. A VO2 peak below 14 mL/kg/min predicts poor surgical outcomes for major cardiac procedures and triggers escalation to advanced therapies. (12)
4. Differentiating cardiac from pulmonary limitation is clinically necessary before committing to a specific treatment pathway.

Treatment Strategies by Underlying Cause

Treatment efficacy depends entirely on matching the intervention to the identified driver. There is no single-drug answer.

Treating Iron Deficiency

Oral ferrous sulfate 325 mg three times daily replenishes iron stores over 8 to 12 weeks in most patients with iron-deficiency anemia. For patients with malabsorption, heart failure, or intolerance to oral iron, intravenous ferric carboxymaltose (15 mg/kg, maximum 1,000 mg per infusion) produces faster repletion. The CONFIRM-HF trial (N=304) showed that IV iron over 52 weeks improved NYHA class in 35% of patients vs. 10% in the placebo group (P<0.001). (13)

Treating Hypothyroidism

Levothyroxine titrated to a TSH of 0.5 to 2.5 mIU/L restores normal thyroid hormone levels over 4 to 8 weeks. Most patients with symptomatic hypothyroidism report measurable improvements in exercise tolerance within 6 to 8 weeks of reaching a therapeutic dose. The starting dose is typically 1.6 mcg/kg/day in otherwise healthy adults and 12.5 to 25 mcg/day in older patients or those with known cardiac disease to avoid provoking arrhythmia.

Treating Testosterone Deficiency

In men with confirmed hypogonadism (total testosterone <300 ng/dL on two morning samples plus symptoms), testosterone replacement therapy (TRT) with testosterone cypionate 200 mg IM every 2 weeks, or transdermal testosterone gel 50 mg daily, produces significant improvements in exercise capacity, muscle mass, and fatigue scores within 12 weeks. The Testosterone Trials (TTrials, N=790) showed that testosterone-treated men had greater improvements in sexual function, mood, and physical function scores vs. Placebo across six simultaneous RCTs. (14) TRT is contraindicated in men with hematocrit above 54%, untreated sleep apnea, or active cardiovascular events.

Treating Cardiac Causes

HFpEF treatment centers on managing comorbidities and improving symptoms. The EMPEROR-Preserved trial (N=5,988) showed that empagliflozin 10 mg daily reduced the composite of cardiovascular death or HF hospitalization by 21% vs. Placebo (hazard ratio 0.79, 95% CI 0.69 to 0.90) in patients with HFpEF, making SGLT2 inhibitors the first drug class with a strong outcome benefit in this population. (15) Supervised exercise rehabilitation (cardiac rehab) independently improves VO2 peak by 10 to 20% over 12 weeks in heart failure patients and carries a Class IA recommendation from the AHA for HFrEF and a Class IIA recommendation for HFpEF. (1)

Treating Deconditioning

Supervised aerobic training at 50 to 80% of VO2 peak or heart rate reserve for 30 to 45 minutes per session, three to five times per week, produces VO2 peak gains of 15 to 25% over 8 to 12 weeks in deconditioned adults. The starting point for patients with severe deconditioning or cardiac comorbidity should be interval training at lower intensities (40 to 50% VO2 peak) to minimize adverse event risk.

GLP-1 Receptor Agonists and Exercise Capacity in Obesity

Obesity independently reduces VO2 peak by increasing the oxygen cost of movement relative to lean body mass. The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg subcutaneously weekly produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo. (16) Weight loss of this magnitude typically improves VO2 peak normalized to body weight by 10 to 20% and reduces the exertional demand of activities of daily living. For patients with obesity-driven exercise intolerance who have not responded to lifestyle modification alone, GLP-1 receptor agonist therapy combined with structured exercise programming addresses both the metabolic and cardiovascular contributors simultaneously.

Red Flags That Require Urgent Evaluation

Most exercise intolerance is not an emergency, but several features indicate the need for same-day or emergency evaluation. Chest pain or pressure that occurs at rest or with minimal exertion, syncope or pre-syncope during activity, a new S3 gallop on auscultation, resting oxygen saturation below 90%, new-onset bilateral leg edema plus dyspnea, and a single-breath diffusing capacity (DLCO) below 40% predicted all warrant urgent workup rather than outpatient scheduling.

The presence of these features alongside exercise intolerance shifts the probability toward acute coronary syndrome, pulmonary embolism, decompensated heart failure, or high-grade aortic stenosis and requires emergency department evaluation, not a scheduled outpatient appointment.

Building the Diagnostic Pathway: A Step-by-Step Approach

Step 1: History and Physical Examination

Onset, duration, trajectory, associated symptoms, medications (beta-blockers reduce heart rate response and can cause fatigue), and cardiovascular risk factors define the pre-test probability of each cause. Physical examination findings, specifically resting heart rate, blood pressure, oxygen saturation, JVD, S3, wheeze, and peripheral edema, narrow the differential before any test is ordered.

Step 2: First-Line Lab Panel Plus ECG

Order the full first-line panel (CBC, CMP, TSH, fasting glucose, HbA1c, iron studies with ferritin, BNP or NT-proBNP, lipid panel) together with a 12-lead ECG. Results guide the next step: a low ferritin triggers iron repletion; an elevated TSH triggers levothyroxine; an elevated BNP triggers echocardiography.

Step 3: Targeted Imaging

Echocardiography is indicated when BNP is elevated, the ECG is abnormal, a cardiac murmur is present, or symptoms do not resolve after treating the identified first-line abnormality. Pulmonary function testing (spirometry with DLCO) is indicated when respiratory symptoms predominate or when a smoking history or occupational exposure increases the probability of obstructive or restrictive lung disease.

Step 4: CPET if Diagnosis Remains Unclear

If steps 1 to 3 fail to identify a sufficient explanation, CPET provides both a quantitative measure of impairment and a mechanistic fingerprint of the limitation. The result directly informs whether cardiac rehabilitation, pulmonary rehabilitation, hormonal optimization, or structured deconditioning reversal is the primary intervention.

Step 5: Treat, Reassess, Repeat CPET at 12 Weeks

Baseline VO2 peak should be repeated at 12 to 16 weeks after initiating treatment. An increase of 1 mL/kg/min or more in VO2 peak is considered a clinically meaningful improvement. Failure to improve signals either non-adherence to therapy, inadequate dose, or a missed co-diagnosis.